In regulating this evolving area of medical practice, state medical boards will need to  strive to achieve an appropriate balance between respecting the autonomy of patients as they seek viable and reasonable treatment options, and adequately safeguarding them against the risks presented by novel, but often unproven and potentially dangerous, interventions. Results from 2017 survey of its member boards  conducted by the FSMB indicate that a third (n=17) of the 51 responding boards have investigated complaints against physicians related to regenerative medicine or stem cell therapy, and that eight of those boards  have taken disciplinary action against physicians for issues relating to regenerative medicine or stem cell therapy.